NCT02389309View on ClinicalTrials.gov

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Advanced Malignant Solid NeoplasmRecurrent Brain NeoplasmRecurrent Malignant Solid NeoplasmRefractory Brain Neoplasm
Interventions
DRUG

Cyclophosphamide

Given PO

DRUG

Dasatinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Temsirolimus

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER